M&A Deal Summary

Midatech Pharma Acquires DARA BioSciences

On December 2, 2015, Midatech Pharma acquired life science company DARA BioSciences

Acquisition Highlights
  • This is Midatech Pharma’s 2nd transaction in the Life Science sector.
  • This is Midatech Pharma’s 1st transaction in the United States.
  • This is Midatech Pharma’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2015-12-02
Target DARA BioSciences
Sector Life Science
Buyer(s) Midatech Pharma
Deal Type Merger
Advisor(s) Aquilo Partners LP (Financial)
K&L Gates (Legal)

Target

DARA BioSciences

Raleigh, North Carolina, United States
DARA BioSciences, Inc. is a clinical stage pharmaceutical development company that acquires high quality, promising therapeutic molecules in early stage development (late pre-clinical or Phase 1).

Search 200,626 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Midatech Pharma

Cardiff, United Kingdom
Category Company
Founded 2000
Sector Life Science
Employees18
Revenue 8M GBP (2017)
DESCRIPTION

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. Midatech Pharma was founded in 2000 and is based in Cardiff, the United Kingdom.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 2
Type (Merger) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 1 of 2
Year (2015) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-12-08 Q Chip

Cardiff, United Kingdom

Q Chip has developed a complementary technology and products that allow sustained release of substances over extended periods of time and will provide a platform to incorporate Midatech’s gold nanoparticle (GNP) compounds for sustained and extended release.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-30 Galena Biopharma - Zuplenz

United States

Galena Biopharma - Zuplenz® (ondansetron) Oral Soluble Film, is approved by the U.S. Food and Drug Administration for use in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV)

Buy -
Mergr

Product

Company

Legal